✦ LIBER ✦

Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status

✍ Scribed by J Janinis; E Efstathiou; C Panopoulos; E Samantas; G Aravantinos; Ch Christodoulou; D Skarlos

Publisher: Springer US
Year: 2000
Tongue: English
Weight: 457 KB
Volume: 17
Category: Article
ISSN: 1357-0560
DOI: 10.1007/bf02796204

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multi-institutional phase II study of te

Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas

✍ Casilda Balmaceda; David Peereboom; Susan Pannullo; Ying Kuen K. Cheung; Paul G. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

## Abstract ## BACKGROUND. The prognosis for patients with recurrent high‐grade gliomas is poor and treatment options are limited. Current chemotherapeutic regimens can improve clinical outcomes, but extend survival by only a few months. Temozolomide is a methylating agent that is typically admini

Phase I pharmacokinetics study of high-d

Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas

✍ B. Tranchand; C. Lucas; P. Biron; B. Giroux; B. Gordon; R. Richards; P. Solere; 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 613 KB

Phase II study of temozolomide and thali

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain : High rate of thromboembolic events (CALGB 500102)

✍ Susan E. Krown; Donna Niedzwiecki; Wen-Jen Hwu; Lydia Hodgson; Alan N. Houghton; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 2 views

Phase-II study of vindesine and hexameth

Phase-II study of vindesine and hexamethylmelamine in patients with relapsing small cell carcinoma of the lung

✍ Rudolf A. Joss; Jean-Paul Obrecht; Walter F. Jungi; Pierre Alberto; Christian Sa 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 163 KB

Twenty-five patients with measurable small cell lung cancer relapsing after first-line chemotherapy were treated with vindesine 3 mg/m2 IV on days 1 and 8 and hexamethylmelamine 100 mg/m2 PO on days 1-14, repeated every 3 weeks. Among 18 fully evaluable patients there was 1 partial remission lasting

Phase II study on neoadjuvant hypertherm

Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas

✍ Carlo R. Rossi; Antonella Vecchiato; Mirto Foletto; Donato Nitti; Vito Ninfo; Ad 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 624 KB

Phase II trial of bisantrene in patients

Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

✍ Thomas P. Miller; Stephen E. Jones; David S. Alberts; Cindy Mackel 📂 Article 📅 1984 🏛 Springer US 🌐 English ⚖ 239 KB

Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without s